Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study
Authors
Swale, AndrewMiyajima, Fabio
Roberts, Paul
Hall, Amanda
Little, Margaret
Beadsworth, Mike BJ
Beeching, Nicholas
Kolamunnage-Dona, Ruwanthi
Parry, Chris M
Pirmohamed, Munir
Issue Date
2014-08-29
Metadata
Show full item recordAbstract
Measurement of both calprotectin and lactoferrin in faeces has successfully been used to discriminate between functional and inflammatory bowel conditions, but evidence is limited for Clostridium difficile infection (CDI). We prospectively recruited a cohort of 164 CDI cases and 52 controls with antibiotic-associated diarrhoea (AAD). Information on disease severity, duration of symptoms, 30-day mortality and 90-day recurrence as markers of complicated CDI were recorded. Specimens were subject to microbiological culture and PCR-ribotyping. Levels of faecal calprotectin (FC) and lactoferrin (FL) were measured by ELISA. Statistical analysis was conducted using percentile categorisation. ROC curve analysis was employed to determine optimal cut-off values. Both markers were highly correlated with each other (r2 = 0.74) and elevated in cases compared to controls (p<0.0001; ROC>0.85), although we observed a large amount of variability across both groups. The optimal case-control cut-off point was 148 mg/kg for FC and 8.1 ng/µl for FL. Median values for FL in CDI cases were significantly greater in patients suffering from severe disease compared to non-severe disease (104.6 vs. 40.1 ng/µl, p = 0.02), but were not significant for FC (969.3 vs. 512.7 mg/kg, p = 0.09). Neither marker was associated with 90-day recurrence, prolonged CDI symptoms, positive culture results and colonisation by ribotype 027. Both FC and FL distinguished between CDI cases and AAD controls. Although FL was associated with disease severity in CDI patients, this showed high inter-individual variability and was an isolated finding. Thus, FC and FL are unlikely to be useful as biomarkers of complicated CDI disease.Citation
Swale, A., Miyajima, F., Roberts, P., Hall, A. et al. (2014) Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study, PLoS ONE, 9(8): e106118. DOI: 10.1371/journal.pone.0106118Publisher
Public Library of Science (PLoS)Journal
PLoS ONEType
Journal articleLanguage
enDescription
© 2014 The Authors. Published by Public Library of Science This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.1371/journal.pone.0106118ISSN
1932-6203EISSN
1932-6203Sponsors
This work was funded by the National Institute for Health Research (NIHR) Biomedical Research Centre in microbial diseases in Liverpool, and by the Medical Research Council [MR/K000551/1]. The authors would also like to thank the NIHR for PhD student funding for Andrew Swale [BRF-2011-028]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.ae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0106118
Scopus Count
Collections
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/